Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012
description
Transcript of Current Uses and Outcomes of Hematopoietic Stem Cell Transplantation 2012
Current Uses and Outcomes of Hematopoietic
Stem Cell Transplantation2012
Summary Slides
SUM12_1.ppt
Location of Centers Participating in the CIBMTR
2012
SUM12_22.pptSlide 2
Tran
spla
nts
SUM12_23.pptSlide 3
Transplant Activity in the U.S.1980-2011
0
2000
4000
6000
8000
10000
12000
14000
AutologousSibling Donor HCTUnrelated Donor HCT
SUM12_24.ppt
Allogeneic Stem Cell Sourcesby Recipient Age
2001-2010
Age £ 20 yrs Age > 20 yrsSlide 4
Tran
spla
nts,
%
0
20
40
60
80
100
2001-2005 2006-2010 2001-2005 2006-2010
Bone Marrow (BM)Peripheral Blood (PB)Cord Blood (CB)
SUM12_25.ppt
Autologous Stem Cell Sourcesby Recipient Age, 2001-2010
Age £ 20 yrs Age > 20 yrsSlide 5
Tran
spla
nts,
%
0
20
40
60
80
100
2001-2005 2006-2010 2001-2005 2006-2010
Bone Marrow (BM)Peripheral Blood (PB)BM + PB
SUM12_26.ppt
Trends in Transplantsby Type and Recipient Age*
2001-2010
* Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma Slide 6
Tran
spla
nts,
%
Allogeneic Transplants Autologous Transplants
0
20
40
60
80
100
2001-2005 2006-2010 2001-2005 2006-2010
<=20 yrs21-40 yrs41-50 yrs51-60 yrs>60 yrs
0
20
40
60
80
100
1990-1996 1997-2003 2004-2010 1990-1996 1997-2003 2004-2010
< 50 years>= 50 years
<60 years>=60 years
SUM12_27.ppt
Trends in Transplantsby Transplant Type and Recipient Age*
1990-2010
* Transplants for AML, ALL, NHL, Hodgkin Disease, Multiple Myeloma Slide 7
Tran
spla
nts,
%
Allogeneic Transplants Autologous Transplants
Indications for Hematopoietic Stem Cell Transplants in the United States, 2010
(Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants)
SUM12_28.pptSlide 8
Num
ber o
f Tra
nspl
ants
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
5,000
5,500
MultipleMyeloma
NHL AML ALL MDS/MPD HD CML AplasticAnemia
OtherLeuk
Non-Malig
Disease
OtherCancer
Allogeneic (Total N=8,860)Autogeneic (Total N=9,026)
Indications for Hematopoietic Stem Cell Transplants for Age £ 20yrs, in the U.S.,
2010(Inflation factor: Auto=1.25 (80%), Allo=1.05 (95%), All Transplants)
SUM12_29.pptSlide 9
Num
ber o
f Tra
nspl
ants
0
100
200
300
400
500
600
700
OtherCancer
ALL AML AplasticAnemia
MDS/MPS HD NHL CML OtherLeuk
Non-Malig
Disease
Allogeneic (Total N=1,479)Autologous (Total N=782)
SUM12_30.ppt
Allogeneic Transplants for Age £ 20yrs,Registered with the CIBMTR, 1993-2010
- by Donor Type and Graft Source -
Slide 10
Num
ber o
f Tra
nspl
ants
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
4,500
5,000
1993-94 1995-96 1997-98 1999-00 2001-02 2003-04 2005-06 2007-08 2009-10
Related BM/PBUnrelated BM/PBUnrelated CB
Allogeneic Transplants for Age > 20yrs,Registered with the CIBMTR, 1993-2010
- by Donor Type and Graft Source -
Slide 11
Num
ber o
f Tra
nspl
ants
SUM12_31.ppt
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
10,000
11,000
12,000
13,000
14,000
1993-94 1995-96 1997-98 1999-00 2001-02 2003-04 2005-06 2007-08 2009-10
Related BM/PBUnrelated BMUnrelated PBUnrelated CB
Unrelated Donor Stem Cell Sourcesby Recipient Age
2001-2010
Age £ 20 yrs Age > 20 yrsSlide 12
Tran
spla
nts,
%
SUM12_32.ppt
0
20
40
60
80
100
2001-2005 2006-2010 2001-2005 2006-2010
Bone Marrow (BM)Peripheral Blood (PB)Cord Blood (CB)
Unrelated Cord Blood Transplants by AgeRegistered with the CIBMTR
2001-2010
Slide 13
Num
ber o
f Tra
nspl
ants
** Data incomplete
SUM12_33.ppt
0
100
200
300
400
500
600
700
800
900
1,000
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
>= 16 years< 16 years
One-
Year
Sur
viva
l, %
Slide 14
One-year Survivalby Year of Transplant, Donor and Age,
Worldwide, 1997-2010- In any remission, Acute Leukemia, CML or MDS-
SUM12_34.ppt
0
20
40
60
80
100
1997 1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
HLA-matched siblings, age <50 yrsUnrelated donor, age <50 yrsHLA-matched siblings, age >=50 yrsUnrelated donor, age >=50 yrs
100-day Mortality after Autologous Transplants, 2010
Slide 15
Mor
talit
y, %
SUM12_35.ppt
0
10
20
30
40
50
Acute Leukemia Non-HodgkinLymphoma
HodgkinDisease
MultipleMyeloma
Early DiseaseIntermediate/Advance DiseaseSensitiveResistantGroup
0
20
40
60
80
100
AML ALL CML MDS/MPS AplasticAnemia
ImmuneDeficiency
100-day Mortality after HLA-identical Sibling Transplants,
2010
Slide 16
Early DiseaseIntermediate DiseaseAdvanced DiseaseChronic PhaseAccelerated PhaseBlast PhaseOther
Mor
talit
y, %
SUM12_36.ppt
0
20
40
60
80
100
AML ALL CML MDS/MPS AplasticAnemia
ImmuneDeficiency
100-day Mortality after Unrelated Donor Transplants,
2008-2009
Slide 17
Early DiseaseIntermediate DiseaseAdvanced DiseaseChronic PhaseAccelerated PhaseBlast PhaseOther
Mor
talit
y, %
SUM12_37.ppt
Causes of Death after Transplants
Done in2009-2010
Autologous
Infection (7%)
Other (17%)
Organ Failure (3%)
New Malignancy (1%)Primary Disease (72%)
Unrelated Donor
Infection (18%)Other (18%)
Organ Failure (8%)
Primary Disease(37%)
New Malignancy (1%)
GVHD (18%)
Slide 18
HLA-identical Sibling
Infection (13%)
Other (16%)
Primary Disease (49%)
GVHD (16%)
Organ Failure (5%)
New Malignancy (1%)
SUM12_38.ppt
Allogeneic TransplantsRegistered with the CIBMTR, 2001-2010
- by Conditioning Regimen Intensity & Age -
** Data incomplete
Slide 19
Num
ber o
f Tra
nspl
ants
SUM12_39.ppt
0
1,000
2,000
3,000
4,000
5,000
6,000
7,000
8,000
9,000
10,000
11,000
2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Reduced Intensity Conditioning, Age >=50 yrsReduced Intensity Conditioning, Age < 50 yrsStandard Myeloablative Conditioning
Allogeneic Transplants after Reduced-intensity Conditioning, by Donor Type,
Registered with CIBMTR 1998-2010
Slide 20
Num
ber o
f Tra
nspl
ants
SUM12_40.ppt
0
500
1,000
1,500
2,000
2,500
3,000
3,500
'98-99 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
Unrelated CBUnrelated PB/BMRelated
Redu
ced
Inte
nsity
Con
ditio
ning, %
Slide 21
Percentage of Reduced Intensity Conditioning Allo-HCTs, Registered with CIBMTR, 1998-2010
- by Year of Transplant & Disease -
SUM12_41.ppt
0
20
40
60
80
100
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008 2009 2010
AMLALLCLLHDMDSFollicular LYMMantle Cell LYMDeffuse Large B-cell LYM
Indications for Hematopoietic Stem Cell Transplants for Age ³ 50yrs, in the U.S.,
2010
SUM12_42.pptSlide 22
Num
ber o
f Tra
nspl
ants
0
500
1,000
1,500
2,000
2,500
3,000
3,500
4,000
Mye/PCD NHL AML MDS/MPS OtherLeukemia
ALL HD CML AA Oth Ca Oth Non-MalignantDisease
Allogenenic (Total N=3,029)Autologous (Total N=5,047)
Allogeneic Transplants in the U.S.,Registered with the CIBMTR, 2007-2011
- by Donor Type -
Slide 23
Tran
spla
nts,
%
SUM12_43.ppt
0
20
40
60
80
100
2007-2008 2009-2010
Matched relatedMismatched relatedUnrelated
SUM12_44.ppt
Hematopoietic Cell Transplant Comorbid Index of U.S. Transplant Recipients
by Group Age2008-2011
Slide 24
Tran
spla
nts,
%
0
20
40
60
80
100
Age <= 20 yrs Age 20-55 yrs Age > 55 yrs
HCT CI=0
HCT CI = 1&2
HCT CI≥ 3
Probability of Survival after HLA-identical Sibling Donor Transplants for AML, 2000-2010
- By Disease Status -
Years0 2 61 3 4 5
Early (N=7,210)
Intermediate (N=1,906)
Advanced (N=2,923)
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
SUM12_2.pptSlide 25
P < 0.0001
Probability of Survival after Unrelated Donor Transplants for AML, 2000-2010
- By Disease Status -
Years0 2 61 3 4 5
Early (N=5,364)
Intermediate (N=3,374)
Advanced (N=3.702)
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
SUM12_3.pptSlide 26
P < 0.0001
Survival after HLA-identical Sibling Donor Transplants for AML, Age <20 yrs, 2000-2010
- by Disease Status -
Years0 2 61 3 4 5
Early (N=1,292)
Intermediate (N=268)
Advanced (N=270)
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
SUM12_4.pptSlide 27
P < 0.0001
Probability of Survival after Autologous Transplants for AML, 2000-2010
- by Disease Status -
Years0 2 61 3 4 5
Early (N=2,139)
Intermediate (N=735)
Advanced (N=152)
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
SUM12_5.pptSlide 28
P < 0.0001
Probability of Survival after Allogeneic Transplants for MDS, 2000-2010- by Disease Status and Donor Type -
SUM12_6.pptSlide 29
Years0 2 61 3 4 5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
Early, sibling donor (N=750)
Early, unrelateddonor (N=890)
Advanced, sibling donor (N=1,407)
Advanced, unrelated donor (N=1,660)
P < 0.0001
Survival after HLA-identical Sibling Donor Transplants for ALL, Age < 20 yrs, 2000-2010
- by Disease Status -
SUM12_7.pptSlide 30
Years0 2 61 3 4 5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P < 0.0001
Early (N=849)
Intermediate (N=1,203)
Advanced (N=210)
Probability of Survival after Unrelated Donor Transplants for ALL, Age < 20 yrs, 2000-2010
- By Disease Status -
SUM12_8.pptSlide 31
Years0 2 61 3 4 5
0
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P < 0.0001
Intermediate (N=2,034)
Advanced (N=289)
Early (N=977)
Survival after HLA-identical Sibling Donor Transplants for ALL, Age ³ 20 yrs, 2000-2010
- By Disease Status -
Slide 32Years
0 2 61 3 4 50
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P < 0.0001
Intermediate (N=715)
Advanced (N=584)
Early (N=2,214)
SUM12_9.ppt
Probability of Survival after Unrelated Donor Transplants for ALL, Age ³ 20 yrs, 2000-2010
- By Disease Status -
Slide 33Years
0 2 61 3 4 50
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P < 0.0001
Intermediate (N=1,075)
Advanced (N=767)
Early (N=1,818)
SUM12_10.ppt
Probability of Survival after HLA-identical Sibling Donor Transplants for CML, 1998-2010
- By Disease Status and Transplant Year -
Slide 34Years
0 2 61 3 4 50
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P < 0.0001
CP, 1998-2000 (N=2,239)
AP, 1998-2000 (N=291)
CP, 2001-2010 (N=2,498)
AP, 2001-2010 (N=360)
SUM12_11.ppt
Survival after Autologous and HLA-matched Sibling Donor Hematopoietic Cell Transplants for CLL, 2000-2010
- by Donor Type and Conditioning Regimen Intensity -
Slide 35Years
0 2 61 3 4 50
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P < 0.0001
Autologous transplant (N=270)
Myeloablative conditioning (N=450)
Reduced-intensity conditioning (N=871)
SUM12_12.ppt
Probability of Survival after Allogeneic Transplants for SAA, 2000-2010
- By Donor Type and Age -
Slide 36Years
0 2 61 3 4 50
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P < 0.0001
£ 20y, Sibling Donor (N=1,375)
> 20y, Sibling Donor (N=1,425)
£ 20y, Unrelated Donor (N=654)
> 20y, Unrelated Donor (N=634)
SUM12_13.ppt
Probability of Survival after Autologous Transplants for Hodgkin Disease, 2000-2010
- By Disease Status -
Slide 37Years
0 2 61 3 4 50
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P < 0.0001
CR (N=2,907)
Not in CR, sensitive (N=3,832)
Not in CR, resistant (N=1,237)
SUM12_14.ppt
Probability of Survival after Allogeneic Transplants for Hodgkin Disease, 2000-2010
- By Conditioning Regimen and Donor Type -
Slide 38Years
0 2 61 3 4 50
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P = 0.226
Sibling Donor (N=356)
Unrelated Donor (N=205)
SUM12_15.ppt
Survival after Autologous Transplants for Follicular Lymphoma, 2000-2010
- By Disease Status -
Slide 39Years
0 2 61 3 4 50
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P < 0.0001
Sensitive (N=2,676)
Resistant (N=279)
SUM12_16.ppt
Probability of Survival after Allogeneic and HLA-identical Sibling Transplants for
Follicular Lymphoma, 2000-2010- By Disease Status -
Slide 40Years
0 2 61 3 4 50
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P = 0.002
Sensitive (N=840)
Resistant (N=212)
SUM12_17.ppt
Probability of Survival after Autologous Transplants for Diffuse Large B-Cell
Lymphoma, 2000-2010- By Disease Status -
Slide 41Years
0 2 61 3 4 50
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P < 0.0001
Sensitive (N=8,891)
Resistant (N=1,033)
SUM12_18.ppt
Probability of Survival after HLA-identical Sibling Transplants for Diffuse Large B-Cell
Lymphoma, 2000-2010- By Disease Status -
Slide 42Years
0 2 61 3 4 50
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P < 0.0001
Sensitive (N=503)
Resistant (N=219)
SUM12_19.ppt
Probability of Survival after Transplants for Mantle Cell Lymphoma, 2000-2010
- By Donor Type -
Slide 43Years
0 2 61 3 4 50
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P < 0.0001
Sibling donor (N=554)
Unrelated donor (N=389)
Autologous (3,173)
SUM12_20.ppt
Probability of Survival after Transplants for Multiple Myeloma, 2000-2010
- By Donor Type -
Slide 44Years
0 2 61 3 4 50
20
40
60
80
100
10
30
50
70
90
0
20
40
60
80
100
10
30
50
70
90
Prob
abilit
y of
Sur
viva
l, %
P < 0.0001
Sibling Donor (N=892)
Unrelated donor (N=380)
Autologous (N27,979)
SUM12_21.ppt